In particular, the serine/threonine kinase BRAF is mutated in ~8% of all cancers. Targeted inhibitors have been designed to block aberrant BRAF, but their efficacy is limited to a subset of mutant ...

This helped pharmaceutical companies develop selective inhibitors of mutated BRAF – including vemurafenib and dabrafenib, which have been approved to treat melanoma. These treatments are frequently ...

While BRAF inhibitors (such as vemurafenib) initially halt tumor growth, many tumors quickly adapt and survive treatment, leading to therapy failure. Unlike traditional resistance driven by ...

A new research perspective was published in , Volume 16, on April 4, 2025, titled "GSK3β activation is a key driver of ...

A new research perspective was published in Oncotarget, Volume 16, on April 4, 2025, titled “GSK3β activation is a key driver ...

The new results from the BREAKWATER study – which is testing the combination of BRAF inhibitor Braftovi (encorafenib) with Eli Lilly's Erbitux (cetuximab) and chemotherapy – showed a ...

While BRAF inhibitors (such as vemurafenib) initially halt tumor growth, many tumors quickly adapt and survive treatment, leading to therapy failure. Unlike traditional resistance driven by ...

While BRAF inhibitors (such as vemurafenib) initially halt tumor growth, many tumors quickly adapt and survive treatment, leading to therapy failure. Unlike traditional resistance driven by ...